Further Keytruda Listing for Advanced Lung Cancer

The drug Keytruda has been added to Pharmaceutical Benefits Scheme for advanced lung cancer as indicated in the Federal Health Minister’s press release.

It is already listed for classical Hodgkin’s lymphoma and unresectable Stage III or Stage IV malignant melanoma. While the extension of the subsidised use of Keytruda is good news, the Society has confirmed that mesothelioma is not covered in the new listing.

Read more on this media release here: https://www.adss.org.au/wp-content/uploads/2018/10/Further-Keytruda-Listing-for-Advanced-Lung-Cancer.pdf